{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:33:54Z","timestamp":1781649234166,"version":"3.54.5"},"reference-count":15,"publisher":"Japanese Society of Internal Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2169\/internalmedicine.7260-26","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T22:09:48Z","timestamp":1779487788000},"source":"Crossref","is-referenced-by-count":1,"title":["Coexistence of Parkinson's Disease and Myasthenia Gravis with Symptom Exacerbation Induced by Biperiden: A Case Report"],"prefix":"10.2169","author":[{"given":"Yuki","family":"Yamanishi","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Ehime University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Miyaue","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Ehime University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikako","family":"Ochi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Ehime University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Ehime University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"Ando","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Ehime University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Nagai","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Ehime University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Mao Z, Nie Q, Xue Z, Li Z. Coexistence of Parkinson's disease and myasthenia gravis: A case report and literature review. Exp Ther Med 28: 282, 2024.","DOI":"10.3892\/etm.2024.12570"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Odajiu I, Davidescu EI, Mitu C, Popescu BO. Patients with Parkinson's disease and myasthenia gravis: A report of three new cases and review of the literature. Medicina (Kaunas) 56: 5, 2020.","DOI":"10.3390\/medicina56010005"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Bonuccelli U, Dotto PD, Lucetti C, et al. Diurnal motor variations to repeated doses of levodopa in Parkinson's disease. Clin Neuropharmacol 23: 28-33, 2000.","DOI":"10.1097\/00002826-200001000-00006"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Chou KL, Stacy M, Simuni T, et al. The spectrum of "off" in Parkinson's disease: What have we learned over 40 years? Parkinsonism Relat Disord 51: 9-16, 2018.","DOI":"10.1016\/j.parkreldis.2018.02.001"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Farmakidis C, Pasnoor M, Dimachkie MM, Barohn RJ. Treatment of myasthenia gravis. Neurol Clin 36: 311-337, 2018.","DOI":"10.1016\/j.ncl.2018.01.011"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Alhaidar MK, Abumurad S, Soliven B, Rezania K. Current treatment of myasthenia gravis. J Clin Med 11: 1597, 2022.","DOI":"10.3390\/jcm11061597"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Pirker W, Katzenschlager R, Hallett M, Poewe W. Pharmacological treatment of tremor in Parkinson's disease revisited. J Parkinsons Dis 13: 127-144, 2023.","DOI":"10.3233\/JPD-225060"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: A review. JAMA 323: 548-560, 2020.","DOI":"10.1001\/jama.2019.22360"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Gao ZG, Liu BY, Cui WY, Li LJ, Fan QH, Liu CG. Anti-nicotinic properties of anticholinergic antiparkinson drugs. J Pharm Pharmacol 50: 1299-1305, 1998.","DOI":"10.1111\/j.2042-7158.1998.tb03349.x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Ueno S, Takahashi M, Kajiyama K, et al. Parkinson's disease and myasthenia gravis: Adverse effect of trihexyphenidyl on neuromuscular transmission. Neurology 37: 832-833, 1987.","DOI":"10.1212\/WNL.37.5.832"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Schreglmann SR, B\u00fcchele F, Sommerauer M, et al. Pyridostigmine for the treatment of orthostatic hypotension in Parkinson disease. Eur J Neurol 24: 545-551, 2017.","DOI":"10.1111\/ene.13260"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Sawada H, Oeda T, Kohsaka M, et al. Early use of donepezil against psychosis and cognitive decline in Parkinson's disease: A randomized controlled trial for 2 years. J Neurol Neurosurg Psychiatry 89: 1332-1340, 2018.","DOI":"10.1136\/jnnp-2018-318107"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Grace J, Amick MM, Friedman JH. A double-blind comparison of galantamine hydrobromide extended release and placebo in Parkinson disease. J Neurol Neurosurg Psychiatry 80: 18-23, 2009.","DOI":"10.1136\/jnnp.2008.144048"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Iwasaki Y, Wakata N, Kinoshita M. Parkinsonism induced by pyridostigmine. Acta Neurol Scand 78: 236, 1988.","DOI":"10.1111\/j.1600-0404.1988.tb03653.x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Zhang Q, Xu E, Li HF, Chan Pi, Zhao Z, Ma J. Parkinson's disease and comorbid myasthenia gravis: A case report and literature review. Front Neurol 14: 1303434, 2024.","DOI":"10.3389\/fneur.2023.1303434"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7260-26\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T03:40:48Z","timestamp":1779507648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7260-26\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":15,"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7260-26","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"7260-26"}}